e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Cystic lung diseases: lung granulomatosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
CCL18 as marker of disease progression in systemic sclerosis
J. Schupp, G. Riemekasten, C. Kollert, B. Jäger, J. Müller-Quernheim, A. Prasse (Freiburg, Berlin, Germany)
Source:
Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Session:
Cystic lung diseases: lung granulomatosis
Session type:
Thematic Poster Session
Number:
692
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Schupp, G. Riemekasten, C. Kollert, B. Jäger, J. Müller-Quernheim, A. Prasse (Freiburg, Berlin, Germany). CCL18 as marker of disease progression in systemic sclerosis. Eur Respir J 2012; 40: Suppl. 56, 692
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Related content which might interest you:
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
Source: Eur Respir J 2011; 38: 1355-1360
Year: 2011
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis
Source: Eur Respir J 2014; 43: 1530-1532
Year: 2014
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Survival and prognostic factors in progressive systemic sclerosis with lung involvement
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis
Source: Eur Respir J 2009; 34: 1376-1382
Year: 2009
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc)
Source: Eur Respir J 2005; 26: Suppl. 49, 202s
Year: 2005
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
The genetics of systemic sclerosis
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016
Year: 2017
Pulmonary function in progressive systemic sclerosis
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
The functional MUC5B rs35705950 promoter polymorphism is associated with IPF but not with systemic sclerosis related interstitial lung disease
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept